These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 35296646)

  • 1. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
    Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
    Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC; Ma F; Kuil A; van Kesteren S; Yasinoglu S; Yang G; Buhrlage SJ; Wang J; Gray NS; Kersten MJ; Treon SP; Pals ST; Spaargaren M
    Leukemia; 2024 Jul; 38(7):1570-1580. PubMed ID: 38454120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
    Yan X; Zhou Y; Huang S; Li X; Yu M; Huang J; Wang J; Ma Z; Jin J; Pan J; Li C; Li F; Jin J
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):697-706. PubMed ID: 29392403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
    Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
    Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.